FindTrial
Sign In

Use-results survey for E-fen buccal tablet

Use-results survey for E-fen buccal tablet

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222899
Enrollment
500
Registered
2015-06-26
Start date
2015-06-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breakthrough pain

Interventions

investigational material(s) Generic name etc : E-fen buccal tablet 50ug 100ug 200ug 400ug 600ug 800ug INN of investigational material : Fentanyl citrate Therapeutic category code : 821 Synthetic narco

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026